News Release

View printer-friendly version << Back

AcelRx Pharmaceuticals to Present at Oppenheimer & Co. Inc. 29th Annual Healthcare Conference

REDWOOD CITY, Calif., March 11, 2019 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the use in medically supervised settings, today announced that management will be presenting at the Oppenheimer 29th Annual Healthcare Conference to be held March 19 – 20. AcelRx management will provide an overview of the business and company updates during the live presentation and will be available for one-on-one investor meetings. 

Details of the event are as follows:

Oppenheimer 29th Annual Healthcare Conference
Date: Wednesday, March 20, 2019
Location: Westin Grand Central, New York, NY
Presentation Time: 2:45 pm ET (11:45 a.m. PT)

The conference presentation will be webcast live and can be accessed through the Investors page at For those not available to listen to the live broadcast, a replay will be archived for 90 days and available through the Investors page on

About AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. AcelRx's proprietary, non-invasive sublingual formulation technology delivers sufentanil with consistent pharmacokinetic profiles. The Company has one approved product in the U.S., DSUVIA (sufentanil sublingual tablet, 30 mcg), known as DZUVEO in Europe, indicated for the management of acute pain severe enough to require an opioid analgesic for adult patients in certified medically supervised healthcare settings, and one product candidate, Zalviso®(sufentanil sublingual tablet system, SST system, 15 mcg) being developed as an innovatively designed patient-controlled analgesia (PCA) system for reduction of moderate-to-severe acute pain in medically supervised settings. DZUVEO and Zalviso are both approved products in Europe. Zalviso is not approved in the U.S. For additional information about AcelRx, please visit

Media Contacts:

Investor Contacts:

Theresa Dolge, Evoke

Raffi Asadorian, CFO, AcelRx


Jessica Ross, Evoke

Brian Korb, Solebury Trout




AcelRx logo. (PRNewsFoto/AcelRx Pharmaceuticals, Inc.) (PRNewsfoto/AcelRx Pharmaceuticals, Inc.)


Cision View original content to download multimedia:

SOURCE AcelRx Pharmaceuticals, Inc.